Opioid overuse has been a long-term concern of postoperative pain management due to its addictive and side-ef-
fect profile. There has been some exploration into the usage of other non-opioid analgesics such as NSAIDs,
but currently there is a lack of research exploring Ketorolac’s significance in ability to reduce opioid-reliance,
ideal route of administration, and adverse reactions in post-operative pain management settings. There also lacks
information regarding Suzetrigine, a Na.V1.8 voltage-gated sodium channel selective inhibitor. In this review,
we contrasted these drugs with other market-available non-opioid analgesics to determine whether Ketorolac and
Suzetrigine are suitable or superior alternatives for post-operative pain management.
We used keywords and MeSH terms, utilizing PubMed, EBSCO, and OpenEvidence. Studies that specifically explored side effect profiles and post-operative pain management in the last 10 years were included.
Suzetrigine has been shown to significantly reduce pain in postoperative settings, with a similar analgesic profile to hydrocodone with more rapid onset of effects. It was generally well tolerated and may be a potential non-addic- tive alternative. Ketorolac has a definitive ability to reduce opioid-requirements and pain levels, but current litera- ture contains contradictions on the superior pain-reducing advantages when contrasted to other NSAIDs. Despite this, patients who received ketorolac have reported significantly fewer adverse reactions. Intramuscular and local administration have been shown to offer specific advantages when contrasted with IV/PO administration. Both Ketorolac and Suzetrigine show significant promise in post-operative pain management, but further research is needed to fully understand the adverse reactions and ideal route of administration.
We used keywords and MeSH terms, utilizing PubMed, EBSCO, and OpenEvidence. Studies that specifically explored side effect profiles and post-operative pain management in the last 10 years were included.
Suzetrigine has been shown to significantly reduce pain in postoperative settings, with a similar analgesic profile to hydrocodone with more rapid onset of effects. It was generally well tolerated and may be a potential non-addic- tive alternative. Ketorolac has a definitive ability to reduce opioid-requirements and pain levels, but current litera- ture contains contradictions on the superior pain-reducing advantages when contrasted to other NSAIDs. Despite this, patients who received ketorolac have reported significantly fewer adverse reactions. Intramuscular and local administration have been shown to offer specific advantages when contrasted with IV/PO administration. Both Ketorolac and Suzetrigine show significant promise in post-operative pain management, but further research is needed to fully understand the adverse reactions and ideal route of administration.